Skip to main content
SpringerLink
Log in

First-line imatinib cost effective for chronic myeloid leukaemia

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2018 US dollars

Reference

  • Nguyen JT, et al. Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia. Value in Health : 7 Aug 2020. Available from: URL: https://doi.org/10.1016/j.jval.2020.05.019

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

First-line imatinib cost effective for chronic myeloid leukaemia. PharmacoEcon Outcomes News 860, 19 (2020). https://doi.org/10.1007/s40274-020-7065-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-7065-1

Search

Navigation